Impact of Antibiotic Prophylaxis on Surgical Site Infections in Cardiac Surgery.
antibiotic prophylaxis
cardiac surgery
cardiopulmonary bypass
cephalosporins
gentamicin
surgical site infection
vancomycin
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
04 Jan 2023
04 Jan 2023
Historique:
received:
26
11
2022
revised:
27
12
2022
accepted:
29
12
2022
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
(1) Background: Cephalosporins (CA) are the first-line antibiotic prophylaxis recommended to prevent surgical site infection (SSI) after cardiac surgery. The combination of vancomycin/gentamicin (VGA) might represent a good alternative, but few studies have evaluated its efficacy in SSI prevention. (2) Methods: A single-centre retrospective study was conducted over a 13-year period in all consecutive adult patients undergoing elective cardiac surgery. Patients were stratified according to the type of antibiotic prophylaxis. CA served as the first-line prophylaxis, and VGA was used as the second-line prophylaxis. The primary endpoint was SSI occurrence at 90 days, which was defined as the need for reoperation due to SSI. (3) Results: In total, 14,960 adult patients treated consecutively from 2006 to 2019 were included in this study, of whom 1774 (12%) received VGA and 540 (3.7%) developed SSI. VGA patients had higher severity with increased 90-day mortality. Nevertheless, the frequency of SSI was similar between CA and VGA patients. However, the microbiological aetiologies were different, with more Gram-negative bacteria noted in the VGA group. (4) Conclusions: VGA seems to be as effective as CA in preventing SSI.
Identifiants
pubmed: 36671286
pii: antibiotics12010085
doi: 10.3390/antibiotics12010085
pmc: PMC9854463
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Interact Cardiovasc Thorac Surg. 2013 May;16(5):643-8
pubmed: 23355648
J Thorac Cardiovasc Surg. 2000 Dec;120(6):1120-30
pubmed: 11088036
Antimicrob Agents Chemother. 1976 Jul;10(1):157-63
pubmed: 825022
Anesthesiology. 2020 Feb;132(2):267-279
pubmed: 31939841
J R Stat Soc Ser A Stat Soc. 2001 Apr 1;174(2):369-386
pubmed: 24926156
J Antimicrob Chemother. 2012 Mar;67(3):541-50
pubmed: 22083832
Scand J Infect Dis. 2012 Dec;44(12):948-55
pubmed: 22831753
Antimicrob Agents Chemother. 2020 Jan 27;64(2):
pubmed: 31712206
BMJ Open. 2019 Nov 3;9(11):e033718
pubmed: 31685516
Ann Surg. 1941 Jul;114(1):19-31
pubmed: 17857852
Clin Microbiol Infect. 2015 Jul;21(7):674.e11-8
pubmed: 25882356
JAMA Surg. 2019 Jul 1;154(7):590-598
pubmed: 31017647
Pharmacotherapy. 2010 Apr;30(4):375-89
pubmed: 20334458
J Hosp Infect. 2018 Nov;100(3):322-328
pubmed: 29733924
Eur J Cardiothorac Surg. 2018 Jan 1;53(1):5-33
pubmed: 29029110
Antimicrob Agents Chemother. 1994 Sep;38(9):2034-40
pubmed: 7811015
Vasc Health Risk Manag. 2020 Dec 15;16:553-559
pubmed: 33364774
AMA Arch Surg. 1955 Jul;71(1):2-6
pubmed: 14387367
PLoS One. 2021 Aug 3;16(8):e0255410
pubmed: 34343185
Ann Surg. 2012 Dec;256(6):1089-92
pubmed: 22824854
Antimicrob Agents Chemother. 2004 Dec;48(12):4665-72
pubmed: 15561842
Clin Med Rev Ther. 2011 Feb 10;3:
pubmed: 21785568
J Chemother. 1991 Apr;3(2):91-7
pubmed: 1875239
Epidemiol Rev. 2022 Jan 14;43(1):118-129
pubmed: 34109972
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Am J Infect Control. 2005 Oct;33(8):450-4
pubmed: 16216658
Front Microbiol. 2010 Dec 08;1:134
pubmed: 21687759
Clin Infect Dis. 2004 May 15;38(10):1357-63
pubmed: 15156470
Infect Control Hosp Epidemiol. 2004 Jun;25(6):468-71
pubmed: 15242193
Int J Surg. 2015 Apr;16(Pt A):69-73
pubmed: 25701616
Antimicrob Agents Chemother. 2003 Jan;47(1):144-7
pubmed: 12499182
J Infect Prev. 2021 Mar;22(2):83-90
pubmed: 33859725
Antimicrob Agents Chemother. 1994 Feb;38(2):396-9
pubmed: 8192475
J Antimicrob Chemother. 2006 Sep;58(3):645-50
pubmed: 16807254
BMC Cardiovasc Disord. 2017 Mar 8;17(1):73
pubmed: 28270114